Electric modulation of sympathetic nervous system

• US 7,937,144 B2
• Filed: 05/17/2007
• Issued: 05/03/2011
• Est. Priority Date: 03/22/2002
• Status: Expired due to Fees

• Current Assignee: Leptos Biomedical, Inc. (Abbott Laboratories Incorporated)
• Original Assignee: Advanced Neuromodulation Systems Incorporated (Abbott Laboratories Incorporated)
• Inventors: Dobak, John Daniel
• Primary Examiner(s): Layno; Carl H
• Assistant Examiner(s): Oropeza; Frances P
• Application Number:
  US11/804,498
• Publication Number:
  US 20070219596A1
• Time in Patent Office: 1,447 Days
• Field of Search: 600/373, 600/377, 600/593, 607/2, 607/115, 607/116, 607/133, 607/118
• US Class Current: 607/2
• CPC Class Codes: A61N 1/36007 of urogenital or gastrointestinal organs, e.g. for incontinence control
• CPC Class Codes: A61N 1/36017 with leads or electrodes penetrating the skin
• CPC Class Codes: A61N 1/36071 Pain
• CPC Class Codes: A61N 1/36085 Eating disorders or obesity

Abstract

A method is described for the treatment of obesity or other disorders, by electrical activation or inhibition of the sympathetic nervous system. This activation or inhibition can be accomplished by electrically stimulating the greater splanchnic nerve or other portion of the sympathetic nervous system using an implantable pulse generator. This nerve activation can result in reduced food intake and increased energy expenditure. Reduced food intake may occur through a variety of mechanisms that reduce appetite and cause satiety. Increased adrenal gland hormone levels will result in increased energy expenditure. Fat and carbohydrate metabolism, which are also increased by sympathetic nerve activation, will accompany the increased energy expenditure.

Claims

1. A method for treating obesity, comprising:

monitoring a patient parameter; and

electrically activating the sympathetic nervous system of said patient so as to achieve a desired change in said monitored parameter;

wherein said monitored parameter is a plasma ghrelin level; and

wherein said electrically activating comprises activating the sympathetic nervous system to achieve a decreased plasma ghrelin level.

2. A method for activating the splanchnic nerve to treat obesity, said method comprising:

implanting a pulse generator within a patient, said pulse generator having programmable treatment parameters;

applying a current pulse to a splanchnic nerve in the patient with said pulse generator;

monitoring the plasma ghrelin level within the patient; and

programming said treatment parameters to maintain plasma ghrelin levels below 250 pg/ml.

3. A method for treating obesity of a patient, comprising:

monitoring electrical activity of a splanchnic nerve of the patient;

monitoring the plasma ghrelin level within the patient; and

electrically activating the sympathetic nervous system of the patient to achieve a decreased plasma ghrelin level.

4. A method for treating obesity of a patient, comprising:

sensing afferent activity of the splanchnic nerve in the patient resulting from feeding of the patient;

monitoring the plasma ghrelin level within the patient; and

electrically activating the sympathetic nervous system of the patient to limit food intake by the patient and to reduce the plasma ghrelin level of the patient.